{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:09:45Z","timestamp":1794038985296,"version":"4.8.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14656566.2026.2690108","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:24:35Z","timestamp":1781519075000},"page":"929-939","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Emerging pharmacotherapies for androgenetic alopecia"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9271","authenticated-orcid":false,"given":"Akriti","family":"Agrawal","sequence":"first","affiliation":[{"name":"All India Institute of Medical Sciences","place":["Bhopal, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-9374","authenticated-orcid":false,"given":"Emilee M.","family":"Dreifus","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-4043","authenticated-orcid":false,"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.25.042"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124088"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.049"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.007"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)80052-8"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.018"},{"issue":"1","key":"e_1_3_4_9_1","first-page":"316","article-title":"Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial","volume":"94","author":"Carvalho Fonseca LP","year":"2026","unstructured":"Carvalho Fonseca LP, Miot HA, Prescendo Chaves CR, et al. Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. J Am Acad Dermatol. 2026;94(1):316\u2013318.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_10_1","first-page":"49","volume-title":"14th world Congress for hair research (WCHR 2026)","author":"Hordinsky M","year":"2026","unstructured":"Clascoterone topical solution 5% phase 3 study design to investigate efficacy and safety in male patients with androgenetic alopecia. In: Hordinsky M, editor. 14th world Congress for hair research (WCHR 2026). Seoul, Korea: 2026 WCHR Organizing Committee; 2026. p. 49."},{"key":"e_1_3_4_11_1","unstructured":"Eirion Therapeutics I. Eirion therapeutics announces potential breakthrough treatment for hair loss based on first-in-man clinical trial results. 2025. Available from: https:\/\/www.prnewswire.com\/news-releases\/eirion-therapeutics-announces-potential-breakthrough-treatment-for-hair-loss-based-on-first-in-man-clinical-trial-results-302344730.html"},{"issue":"2","key":"e_1_3_4_12_1","first-page":"197","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro","volume":"18","author":"Rosette C","year":"2019","unstructured":"Rosette C, Rosette N, Mazzetti A, et al. Cortexolone 17\u03b1-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197\u2013201.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_13_1","unstructured":"Cassiopea Inc. Winlevi (clascoterone) cream 1%: US prescribing information. US Food and Drug Administration;2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213433s000lbl.pdf"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.087"},{"key":"e_1_3_4_15_1","unstructured":"Clascoterone 5% delivers strong Phase 3 hair-growth results. 2025 [cited 2026 Jan 10]. Available from: https:\/\/www.dermatologytimes.com\/view\/clascoterone-5-delivers-strong-phase-3-hair-growth-results"},{"key":"e_1_3_4_16_1","unstructured":"A study to evaluate the efficacy and safety of clascoterone 5% solution in the treatment of male androgenetic alopecia (SCALP-2). ClinicalTrialsgov; 2023."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030663"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2574304"},{"key":"e_1_3_4_20_1","unstructured":"Kintor Pharma\u2019s GT20029 Phase II trial meets primary endpoint. 2024 [cited 2026 Jan 10]. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/kintor-trial-aga-treatment\/"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050468"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1277"},{"key":"e_1_3_4_23_1","unstructured":"May E Jool S Kr\u00e4tzschmar J et al. Inventors; World Intellectual Property Organization assignee. Prolactin receptor antibody for male and female pattern hair loss patent WO2019011719A1. 2019."},{"key":"e_1_3_4_24_1","unstructured":"HopeMed advances its androgenetic alopecia treatment to Phase II trials. 2025. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/hopemed-advances-its-androgenetic-alopecia-treatment-to-phase-ii-trials\/"},{"key":"e_1_3_4_25_1","volume-title":"ABS-201\u2122 for androgenetic alopecia [Internet]","author":"Absci Corporation","year":"2024","unstructured":"Absci Corporation. ABS-201\u2122 for androgenetic alopecia [Internet]. Vancouver (WA): Absci Corporation; 2024. Available from: https:\/\/www.absci.com\/abs-201-case-study\/"},{"key":"e_1_3_4_26_1","volume-title":"Corporate presentation Fall 2025","author":"Absci C","year":"2025","unstructured":"Absci C. Corporate presentation Fall 2025. Vancouver (WA): Absci Corporation; 2025."},{"key":"e_1_3_4_27_1","volume-title":"Generative AI Drug creation: aBS-201 KOL seminar","author":"Absci C","year":"2025","unstructured":"Absci C. Generative AI Drug creation: aBS-201 KOL seminar. Vancouver (WA): Absci Corporation; 2025."},{"key":"e_1_3_4_28_1","volume-title":"Absci announces first participants dosed in Phase 1\/2a HEADLINE\u2122 trial of AI-designed antibody ABS-201\u2122 for androgenetic alopecia [press release]","author":"Absci Corporation","year":"2025","unstructured":"Absci Corporation. Absci announces first participants dosed in Phase 1\/2a HEADLINE\u2122 trial of AI-designed antibody ABS-201\u2122 for androgenetic alopecia [press release]. Vancouver (WA): Absci Corporation; 2025 Dec 4. Available from: https:\/\/investors.absci.com\/node\/10086\/pdf"},{"key":"e_1_3_4_29_1","unstructured":"Study of ABS-201 evaluating single and multiple Ascending doses in healthy adults with and without Androgenetic Alopecia. ClinicalTrialsgov. 2025."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44478"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06172-8"},{"key":"e_1_3_4_32_1","unstructured":"Amplifica\u2019s AMP-303 study unveils new hope for hair loss treatments. Amplifica Bio. 2025."},{"key":"e_1_3_4_33_1","unstructured":"AMP-303 shows promise in male pattern baldness. The Derm Dig [Internet]. 2024 Sep 30. Available from: https:\/\/thedermdigest.com\/amp-303-shows-promise-in-male-pattern-baldness\/"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3575"},{"key":"e_1_3_4_35_1","volume-title":"Pelage presents late-breaking data at AAD 2024 meeting demonstrating PP405 activates human hair follicle stem cells ex vivo and in Phase 1 clinical study [press release]","author":"Pelage Pharmaceuticals","year":"2024","unstructured":"Pelage Pharmaceuticals. Pelage presents late-breaking data at AAD 2024 meeting demonstrating PP405 activates human hair follicle stem cells ex vivo and in Phase 1 clinical study [press release]. Los Angeles (CA): Pelage Pharmaceuticals; 2024 Mar 9. Available from: https:\/\/pelagepharma.com\/press-releases\/pelage-presents-late-breaking-data-at-aad-2024-meeting-demonstrating-pp405-activates-human-hair-follicle-stem-cells-ex-vivo-and-in-phase-1-clinical-study\/"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.06.1215"},{"key":"e_1_3_4_37_1","unstructured":"Pelage\u2019s PP405 demonstrates efficacy in Phase 2a trial for androgenetic alopecia. Dermatol Times. 2025."},{"key":"e_1_3_4_38_1","unstructured":"Pelage P. Pelage pharmaceuticals announces positive Phase 2a clinical trial results for PP405 in regenerative hair loss therapy: Pelage pharmaceuticals. 2025 Available from: https:\/\/pelagepharma.com\/press-releases\/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy\/"},{"key":"e_1_3_4_39_1","unstructured":"ET-02 Androgenic Alopecia [Web page]. TouchDERMA; [cited 2026 May 28]. Available from: https:\/\/touchderma.com\/insight\/et-02-androgenic-alopecia\/"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05785.x"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1945527"},{"key":"e_1_3_4_42_1","unstructured":"About VDPHL01. VeraDermics. 2025."},{"key":"e_1_3_4_43_1","unstructured":"Veradermics completes enrollment in Phase 2\/3 male androgenetic alopecia trial. FirstWordpharma. 2025."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20508"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf012"},{"key":"e_1_3_4_46_1","unstructured":"Samson Clinical Operations Pty L. Efficacy & safety of minoxidil SL tablets in men with AGA [Clinical trial registry record] ClinicalTrialsgov. 2025."},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1209439"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256574"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-025-00738-6"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.34133\/research.0780"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104013"},{"key":"e_1_3_4_52_1","article-title":"Exploring the potential of thyroid receptor \u03b2 for treating androgenetic alopecia","author":"Santoro C","year":"2025","unstructured":"Santoro C. Exploring the potential of thyroid receptor \u03b2 for treating androgenetic alopecia. Am J Manag Care [Internet]. 2025 Jun 25. Available from: https:\/\/www.ajmc.com\/view\/exploring-the-potential-of-tr-for-treating-androgenetic-alopecia","journal-title":"Am J Manag Care [Internet]"},{"key":"e_1_3_4_53_1","unstructured":"Investigating thyroid receptor therapy\u2019s role in combatting androgenetic alopecia. Dermatol Times. 2025."},{"key":"e_1_3_4_54_1","unstructured":"TDM-105795 Phase 2 success: stimulates hair growth in pattern baldness. Synapse; 2024. Available from: https:\/\/synapse.patsnap.com\/article\/tdm-105795-phase-2-success-stimulates-hair-growth-in-pattern-baldness"},{"key":"e_1_3_4_55_1","unstructured":"ClinicalTrials.gov. Study of TDM-105795 following topical administration in male subjects with androgenetic. Alopecia: U.S. National Library of Medicine; [cited 2026 Mar 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05802173"},{"key":"e_1_3_4_56_1","volume-title":"Safety, tolerability and pharmacokinetics of KX826 in healthy male subjects with androgenetic alopecia (NCT04984707) [clinical trial registry]","author":"ClinicalTrials.gov","year":"2021","unstructured":"ClinicalTrials.gov. Safety, tolerability and pharmacokinetics of KX826 in healthy male subjects with androgenetic alopecia (NCT04984707) [clinical trial registry]. Bethesda (MD): U.S. National Library of Medicine; 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04984707"},{"key":"e_1_3_4_57_1","unstructured":"HairScience. Kintor USA Clinical Trial Results for Pyrilutamide (KX-826) 2023 [HairScience.org]. Available from: https:\/\/hairscience.org\/news\/kintor-usa-clinical-trial-pyrilutamide-results\/"},{"key":"e_1_3_4_58_1","unstructured":"Kintor Pharmaceutical L. Kintor pharma announces successful completion of Phase II clinical trial of KX-826 for treatment of Androgenetic Alopecia in the U.S. PR Newswire. 2023."},{"key":"e_1_3_4_59_1","unstructured":"Inc SKP. Phase III study of KX-826 with adult male patients with androgenetic Alopecia. ClinicalTrialsgov; 2023. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06126965"},{"key":"e_1_3_4_60_1","unstructured":"Health PH. Pyrilutamide (KX-826): a promising future treatment for hair loss. 2023. Available from: https:\/\/perfecthairhealth.com\/pyrilutamide-kx-826-a-promising-future-treatment-for-hair-loss\/"},{"key":"e_1_3_4_61_1","volume-title":"Cosmetics with KX-826 as the core ingredient launched for sale [press release]","author":"Pioneering Pharmaceuticals","year":"2024","unstructured":"Pioneering Pharmaceuticals. Cosmetics with KX-826 as the core ingredient launched for sale [press release]. Beijing (China): Pioneering Pharmaceuticals; 2024 Jul 10. Available from: https:\/\/en.kintor.com.cn\/news_details\/3.html"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00510"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05544-w"},{"key":"e_1_3_4_64_1","unstructured":"Medical B. siRNA for Hair Health: what you need to know about CosmeRNA & SAMiRNA 2025 [Bauman Medical]. Available from: https:\/\/www.baumanmedical.com\/sirna-for-hair-health-what-you-need-to-know-about-cosmerna-samirna\/"},{"key":"e_1_3_4_65_1","unstructured":"Food US Drug A. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Web page. 2026."},{"key":"e_1_3_4_66_1","first-page":"59","article-title":"Regulation (EC) No 1223\/2009 of 30 November 2009 on cosmetic products (recast) [legislation]","volume":"342","author":"European Parliament and Council of the European Union","year":"2009","unstructured":"European Parliament and Council of the European Union. Regulation (EC) No 1223\/2009 of 30 November 2009 on cosmetic products (recast) [legislation]. Official Journal of the European Union. 2009;L342:59\u2013209. https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/cosmetic_1223_2009_regulation_en_0.pdf","journal-title":"Official Journal of the European Union"},{"key":"e_1_3_4_67_1","volume-title":"Cosmetics act [Internet]","author":"Korean Legislation Research Institute","year":"2018","unstructured":"Korean Legislation Research Institute. Cosmetics act [Internet]. Seoul (Republic of Korea): Korean Legislation Research Institute; 2018. Available from: https:\/\/elaw.klri.re.kr\/eng_service\/lawView.do?hseq=50282&lang=ENG"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14234"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.048"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.144162"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13096"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.03.001"},{"issue":"4","key":"e_1_3_4_73_1","first-page":"414","article-title":"Side effects related to 5 \u03b1-reductase inhibitor treatment of hair loss in women: a review","volume":"15","author":"Seale LR","year":"2016","unstructured":"Seale LR, Eglini AN, McMichael AJ. Side effects related to 5 \u03b1-reductase inhibitor treatment of hair loss in women: a review. J Drugs Dermatol. 2016;15(4):414\u2013419.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.034"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.023"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2690108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2690108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2690108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:43Z","timestamp":1784115463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2690108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14656566.2026.2690108"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2690108","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}